Posted by Michael Wonder on 08 Aug 2024
Neurogene announces RMAT designation for NGN-401 investigational gene therapy for Rett syndrome
7 August 2024 - Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome.
Neurogene today announced that NGN-401 received regenerative medicine advanced therapy designation from the US FDA for the treatment of Rett syndrome.
